Summary
This Eli Lilly & Co. (LLY) 8-K filing announces a significant addition to its Board of Directors with the appointment of Dr. Mary Lynne Hedley, effective May 15, 2022. Dr. Hedley brings a wealth of experience in the biotechnology and oncology sectors, having co-founded TESARO, Inc., a successful oncology therapeutics company acquired by GlaxoSmithKline. Her expertise in scientific research, development, and commercialization is expected to be a valuable asset to Lilly's strategic direction. Dr. Hedley's appointment to the Board's Ethics and Compliance Committee and Science and Technology Committee underscores Lilly's commitment to robust governance and innovation. Her independence is confirmed, and she will participate in the company's standard director compensation program. This move signals Lilly's continued focus on strengthening its leadership with seasoned industry professionals.
Key Highlights
- 1Eli Lilly & Co. has appointed Dr. Mary Lynne Hedley to its Board of Directors, effective May 15, 2022.
- 2Dr. Hedley is a seasoned executive with extensive experience in the biotechnology and oncology fields, notably as a co-founder of TESARO, Inc.
- 3Her background includes leadership roles in research and development, operations, and business development at prominent biotech companies.
- 4Dr. Hedley will serve on the Ethics and Compliance Committee and the Science and Technology Committee of the Board.
- 5The Board has confirmed Dr. Hedley's independence under NYSE and company guidelines.
- 6There are no undisclosed arrangements or transactions between Dr. Hedley and the company.
- 7The appointment was announced via a press release dated May 6, 2022, which is attached as an exhibit.